These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29972081)

  • 1. Model-based pharmacokinetic and pharmacodynamic analysis for acute effects of a small molecule inhibitor of diacylglycerol acyltransferase-1 in the TallyHo/JngJ polygenic mouse.
    Chae YJ; Song JS; Ahn JH; Bae MA; Lee KR
    Xenobiotica; 2019 Jul; 49(7):823-832. PubMed ID: 29972081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans.
    Maciejewski BS; LaPerle JL; Chen D; Ghosh A; Zavadoski WJ; McDonald TS; Manion TB; Mather D; Patterson TA; Hanna M; Watkins S; Gibbs EM; Calle RA; Steppan CM
    Am J Physiol Gastrointest Liver Physiol; 2013 Jun; 304(11):G958-69. PubMed ID: 23558010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core.
    Dow RL; Andrews M; Aspnes GE; Balan G; Michael Gibbs E; Guzman-Perez A; Karki K; Laperle JL; Li JC; Litchfield J; Munchhof MJ; Perreault C; Patel L
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6122-5. PubMed ID: 21908190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice.
    Kim JH; Stewart TP; Soltani-Bejnood M; Wang L; Fortuna JM; Mostafa OA; Moustaid-Moussa N; Shoieb AM; McEntee MF; Wang Y; Bechtel L; Naggert JK
    J Endocrinol; 2006 Nov; 191(2):437-46. PubMed ID: 17088413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster.
    King AJ; Segreti JA; Larson KJ; Souers AJ; Kym PR; Reilly RM; Zhao G; Mittelstadt SW; Cox BF
    J Pharmacol Exp Ther; 2009 Aug; 330(2):526-31. PubMed ID: 19478132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.
    Dow RL; Andrews MP; Li JC; Michael Gibbs E; Guzman-Perez A; Laperle JL; Li Q; Mather D; Munchhof MJ; Niosi M; Patel L; Perreault C; Tapley S; Zavadoski WJ
    Bioorg Med Chem; 2013 Sep; 21(17):5081-97. PubMed ID: 23871442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors.
    Hong DJ; Jung SH; Kim J; Jung D; Ahn YG; Suh KH; Min KH
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):227-234. PubMed ID: 31752563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of thiazole containing biaryl analogs as diacylglycerol acyltransferase 1 (DGAT1) inhibitors.
    Kadam KS; Jadhav RD; Kandre S; Guha T; Reddy MM; Brahma MK; Deshmukh NJ; Dixit A; Doshi L; Srinivasan S; Devle J; Damre A; Nemmani KV; Gupte A; Sharma R
    Eur J Med Chem; 2013 Jul; 65():337-47. PubMed ID: 23735282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies for metabolic diseases: Small-molecule diacylglycerol acyltransferase (DGAT) inhibitors.
    Naik R; Obiang-Obounou BW; Kim M; Choi Y; Lee HS; Lee K
    ChemMedChem; 2014 Nov; 9(11):2410-24. PubMed ID: 24954424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets.
    Yamamoto T; Yamaguchi H; Miki H; Shimada M; Nakada Y; Ogino M; Asano K; Aoki K; Tamura N; Masago M; Kato K
    Eur J Pharmacol; 2010 Aug; 640(1-3):243-9. PubMed ID: 20478303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice.
    Tomimoto D; Okuma C; Ishii Y; Kobayashi A; Ohta T; Kakutani M; Imanaka T; Ogawa N
    J Pharmacol Sci; 2015 Sep; 129(1):51-8. PubMed ID: 26354408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of indolyl acrylamide derivatives as human diacylglycerol acyltransferase-2 selective inhibitors.
    Lee K; Kim M; Lee B; Goo J; Kim J; Naik R; Seo JH; Kim MO; Byun Y; Song GY; Lee HS; Choi Y
    Org Biomol Chem; 2013 Feb; 11(5):849-58. PubMed ID: 23242135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity.
    Kim MO; Lee SU; Lee HJ; Choi K; Kim H; Lee S; Oh SJ; Kim S; Kang JS; Lee HS; Kwak YS; Cho S
    Biol Pharm Bull; 2013; 36(7):1167-73. PubMed ID: 23585481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.
    Yan J; Wang G; Dang X; Guo B; Chen W; Wang T; Zeng L; Wang H; Hu Y
    Bioorg Med Chem; 2017 Sep; 25(17):4701-4714. PubMed ID: 28739155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol.
    Morentin Gutierrez P; Yates J; Nilsson C; Birtles S
    Pharmacol Res Perspect; 2019 Apr; 7(2):e00465. PubMed ID: 30899516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
    Zhao G; Souers AJ; Voorbach M; Falls HD; Droz B; Brodjian S; Lau YY; Iyengar RR; Gao J; Judd AS; Wagaw SH; Ravn MM; Engstrom KM; Lynch JK; Mulhern MM; Freeman J; Dayton BD; Wang X; Grihalde N; Fry D; Beno DW; Marsh KC; Su Z; Diaz GJ; Collins CA; Sham H; Reilly RM; Brune ME; Kym PR
    J Med Chem; 2008 Feb; 51(3):380-3. PubMed ID: 18183944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.
    King AJ; Segreti JA; Larson KJ; Souers AJ; Kym PR; Reilly RM; Collins CA; Voorbach MJ; Zhao G; Mittelstadt SW; Cox BF
    Eur J Pharmacol; 2010 Jul; 637(1-3):155-61. PubMed ID: 20385122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of PF-04620110, a novel inhibitor of diacylglycerol acyltransferase-1, in rat plasma using liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic studies.
    Lee KR; Choi SH; Song JS; Seo H; Chae YJ; Cho HE; Ahn JH; Ahn SH; Bae MA
    Biomed Chromatogr; 2013 Jul; 27(7):846-52. PubMed ID: 23420715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of [trans-5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl]acetic acid monobenzenesulfonate (JTT-553), a novel acyl CoA:diacylglycerol transferase (DGAT) 1 inhibitor.
    Tomimoto D; Okuma C; Ishii Y; Akiyama Y; Ohta T; Kakutani M; Ohkuma Y; Ogawa N
    Biol Pharm Bull; 2015; 38(2):263-9. PubMed ID: 25747985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice.
    Choi JH; Choi JN; Lee SY; Lee SJ; Kim K; Kim YK
    Arch Pharm Res; 2010 Feb; 33(2):237-42. PubMed ID: 20195824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.